Objective: Signal detection is a technique in pharmacovigilance for the early detection of new, rare reactions (desired or undesired) of a drug. This study aims to compare and appraise the performance of data mining algorithms used in signal detection. Method: Most commonly used three data mining algorithms (DMAs) (Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR) and Information Component (IC)) were selected and applied retrospectively in USFDA Adverse Event Reporting System database to detect five confirmed Drug Event Combinations. They were selected in such a way that the drug is withdrawn from the market or label change between 2006-2015. A value of ROR-1.96SE>1, PRR≥2, χ2>4 or IC-2SD>0 were considered as the positive signal. The data mining algorithms were compared for their sensitivity and early detection. Result: Among the three data mining algorithms, Information Component was found to have a maximum sensitivity (100%) followed by Reporting Odds Ratio (60%) and Proportional Reporting Ratio (40%). Sensitivity associated with the number of reports per drug event combination and early signal detection suggested that information component needs comparatively fewer reports to show positive signal than the other two data mining algorithms. ROR and PRR showed comparable results. Conclusion: Early detection of a reaction is possible using signal detection technique. Information component was found to be sensitive method compared with other two data mining algorithms in FDA Adverse Event Reporting System database. As the number of reports of drug event combination increased, the sensitivity and comparability of data mining algorithm also increased. 445 RESULTS ROR, PRR and IC were applied on USFDA AERS database to detect five confirmed DEC and to compare the DMAs.
INTRODUCTION
The US Food and Drug Administration (FDA) has maintained the Adverse Events Reporting System (AERS) database since 1968 with the intention of continuous monitoring of drugs during the post-marketing surveillance.
1 AERS database is a collection of suspected Adverse Event (AEs) reports from pharmaceutical companies, consumers and healthcare professionals. 2 To date, FDA AERS database contains more than 10 million AE reports and receive nearly half a million each year. Many approaches have been adopted into post-marketing studies, including prescription-event monitoring (PEM), spontaneous reporting, case review, observational study and drug utilization review.
Compared to clinical trials and traditional epidemiologic studies, the computer-assisted Data Mining Algorithms (DMAs) are relatively new and characterized by providing a fast and efficient way of detecting possible Adverse Drug Reactions (ADRs) signal. 3 Several DMAs have been well described in the literature, mainly including the Reporting Odds Ratio (ROR), 4 Multi-item Gamma Poisson Shrinker (MGPS), 5 the Proportional Reporting Ratio (PRR), 6 and the Information Component (IC). 7 By integrating such computer-aided techniques, incorporating statistical analyses and centralizing different data resources, it is not only possible to minimize the human efforts and errors but also assist the regulatory bodies and safety councils. 8 A.M. Wilson 9 defined 'data mining' as 'the use of statistical techniques, such as disproportionality measures for database or large information sources for extracting an unknown information' . At present, three major DMAs such as the PRR of the Netherlands, the ROR of the United Kingdom and the IC of the WHO are widely used. [9] [10] Speaking of the DMAs, one of the frequently discussed and yet to be resolved question is which algorithm has superior performance. The absence of gold standard, 11 enormous ADR reports, different coding systems, a wide range of data mining processes and structural dissimilarities of databases made the comparisons across the DMAs difficult. Limited studies have been conducted to compare the DMAs thus far. This study aims to compare and appraise the performance of signal detection techniques used in data mining.
METHODOLOGY
Most commonly used three DMAs (ROR, PRR and IC) were selected based on a literature survey. DMAs were applied retrospectively (Table 1 and 2) in US FDA AERS database to detect five confirmed Drug Event Combinations (DEC) ( 
Sibutramine
Sibutramine was approved in 1997 as an oral anorexiant. Later in 2010, it was withdrawn from the market due to severe cardio and cerebrovascular accidents and associated death. A total of 4182 DEC were reported from 2005Q1 to 2010Q4 in USFDA AERS database (Table 4 ). Only IC, 0.28 (95% CI, 0.05 -0.54) showed a positive signal for sibutramine from 2009Q1 whereas ROR and PRR failed to show a positive signal for the given DEC in the specified duration. PT used for data mining were "cerebrovascular disease" and "stroke". Positive signals were highlighted with bold letters.
Rosiglitazone
Rosiglitazone was approved in 1999 for diabetes mellitus and was withdrawn from the market because of cardiac toxicity and associated death in 2010. A total of 11839 DEC were reported from 2005Q1 to 2010Q4 in USFDA AERS database (Table 4) for the given DEC in the specified period. PT used for data mining were "Myocardial Infarction" (MI). Positive signals were highlighted with bold letters.
Sitagliptin
Sitagliptin was approved in 2006 for diabetes mellitus. Recently (2012), the labelling criteria of sitagliptin had changed to include a black box warning of renal failure associated with sitagliptin. A total of 854 DEC were reported from 2005Q1 to 2015Q2 in USFDA AERS database (Table  5 ). Only IC, 0.1 (95% CI, 0 -0.23) showed positive signal (from 2011Q2) whereas ROR and PRR failed to show positive signal. PT used for data mining were "renal failure acute", "creatinine renal clearance decreased" and "blood creatinine increases". Positive signals were highlighted with bold letters.
Canagliflozin
Canagliflozin is approved in 2013 for the treatment of Diabetes Mellitus and in 2015 it was subjected to a change in labelling criteria to incorporate safety warning of Urinary Tract Infection (UTI). A total of 566 DEC were reported from 2013Q2 to 2015Q4 in USFDA AERS database (Table 5) . IC, 0.78 (95% CI, 0.53-0.98) and ROR, 1.42 (95% CI, 1.11-1.94) showed a positive signal at 2015Q3 and 2015Q4 respectively. PT used for data mining were "urinary tract infection". Positive signals were highlighted with bold letters.
Sensitivity of DMAs
The sensitivity of three DMAs were assessed (Table 6 ) in accordance with its potential to identify the signals prior to the withdrawal date. Out of 
Drug of Interest Other Drugs

ADR of interest
p(x) = Probability of a suspected drug being reported in a case report; p(y) = Probability of a suspected event being reported in a case report; p(x, y) = Probability that suspected drug and event simultaneously being reported in a case report 
Study Procedure
FDA AERS database downloaded from USFDA official website. The database converted into excel from text format for the ease of analysis and computation. Primary suspects and secondary suspect case IDs of the drug of interest were noted from DRUG file. AE pertaining to those case IDs were filtered and listed. Different parameters of the DMA equation (Table 1) were computed and finally applied to the equation (Table 2) .
Statistical analysis
The threshold was predefined as PRR of ≥2.0 with a Chi-squared test of ≥4.0, at least three reports (n ≥3) of that preferred term(PT), IC with IC-2SD>0 and ROR with ROR-1.96SE>1. The confidence interval (95%) were considered to be statistically significant. 13 tively fewer reports to show positive signal than ROR and PRR. Parallel to the above result, ROR and PRR are almost identical in their sensitivity.
DISCUSSION
In this study, the most commonly used three DMAs are ROR, PRR and IC which are applied retrospectively in USFDA AERS database to detect five known and confirmed ADRs associated with the drug withdrawal or change in labelling criteria. Further comparisons across the selected DMAs were executed to identify the sensitivity by means of early detection and number of reports. Hitherto, there is no clearly defined method to compare the DMAs with respect to their sensitivity or performance. The major drawback in comparing the DMAs is the lack of golden standards.
14 In E.P. van Puijenbroek, A. Bate 11 study, they compared the DMAs like PRR, Yule's Q and Chi-square with IC, which was considered as a golden standard by them. Another study conducted by K. Kubota 15 in Japanese spontaneous reports, compared five DMAs. According to Kubota et al., the number of five, IC showed maximum sensitivity (100%) followed by ROR (60%) and PRR (40%).
The sensitivity of DMA based on Early Detection
DMAs were assessed for their ability for early detection of a signal (Table 7) . Index Date of Withdrawn/Label change (IDW/L) were identified from literature or official websites of USFDA. The quadrant from which DEC started showing positive signals were allocated as Index Date of Detection (IDD). Early detection was quantified by IDD subtracted from IDW/L. IC was found to be the most sensitive, as it detects positive signal well before other DMAs and there is no remarkable difference in sensitivity of early detection between ROR and PRR.
Sensitivity associated with the number of reports per DEC
DMAs were assessed for their sensitivity with respect to the number of reports required to show positive signal (Figure 1 ). Sensitivity associated with the number of reports per DEC suggested that IC need compara- '√' means that the DMA could identify the signals prior to the withdrawal date; 'X' means that algorithms did not identify the signals prior to the withdrawal date. DECs identified as signals were considered as the measure of sensitivity. Compared to the above two studies, 11, 15 the findings of the present study seemed to be more reliable because the reference standard considered is more robust. Comparison of DMAs is possible in many ways, but the main aspect which directly influences the DMA values is the number of reports. Thus, according to this study, a cumulative number of reports should be considered as the measure of sensitivity. Early detection of ADRs is the main advantage of DMAs, [16] [17] therefore it can be considered as a measure of sensitivity. This study indicates that IC is more sensitive in terms of early detection as well as the number of reports. However, among the DMAs, the sensitivity difference is statistically not significant. Moreover, the sensitivity of DMAs may vary if a different database is used hence, we cannot conclude that IC is the most sensitive DMA. Nevertheless, for a given set of data and DMAs, IC showed more sensitivity than other DMAs. It has been observed that the sensitivity is proportional to the number of reports. According to V.G. Koutkias and M.-C. Jaulent, 18 the number of reports is an important factor for signal strength. According to the literature review, it was observed that no study has been attempted to compare DMA to identify the sensitive method among the existing algorithms. We comply with P. Waller 19 study, as the selection of DMAs should be done on the basis of their specificity, sensitivity and predictive value in addition to a factor observed from our study. Early detection of ADR plays a vital role which may reduce the casualties and provide sufficient time for a regulatory decision. It is not surprising that IDD is earlier than IDW because once the positive signal is identified, FDA requires adequate time to evaluate the situation, assess the risk-benefit profile of the drug and for a regulatory decision. However, the use of DMAs could trigger the initiation of this process earlier by recognizing signals in advance. Few studies have compared the traditional method of ADR detection with computer-based signal detection techniques. A study conducted by A.W. I 20 concluded that DMAs detected safety signals well before the conventional ways. According to D.J. Graham, 21 there were 88,000-140,000 excess of cardiac disorders associated with rofecoxib. It could have been reduced if the safety signal was detected earlier.
We rely on the progression between the early detection of an ADR signal to the final decision that drug withdrawal or labelling change could more likely be acquired due to the earlier detection of ADR signals as a result of the applications of DMAs. Consequently, the time when the FDA makes a decision will correspondingly occur earlier.
Limitations of the study
There are some concerns regarding FDA AERS database. Under-reporting is the main concern with regards to any spontaneous reporting system (SRS) database. SRS will not reflect the actual picture of the scenario. Thus, more often the situation was underestimated. Secondly, the reporting may get biased when there is a change in labelling criteria or any special updates regarding an ADR of the drug. As a result, over-reporting of that particular ADR will occur which will decrease the signal strength of other ADRs of the same drug (change in Ni value will affect the signal strength). The selection of brand names for data mining is another limitation which we had come across. FDA AERS database is a collection of ADR reports around the world but the main contributor is United States (US). The brand names used for data mining in this study mainly focused on the US, European countries and India. Thus, the chances of missing data cannot be ruled out.
CONCLUSION
The aim of the study was to compare and appraise the performance of signal detection techniques used in data mining. It is the first study attempted to address the importance of early detection of ADR and identification of the sensitive method. Even though there is no statistically significant difference among three DMAs, IC was found to be sensitive method compared with other two DMAs in FDA AERs database. The sensitivity and comparability of DMA is proportionate to the number of reports of DEC.
